南京恒扬医药

Nanjing Hengyang Pharmaceutical is a clinical-stage biotechnology company based in Nanjing, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing significant unmet medical needs in metabolic diseases, oncology, and inflammatory disorders. Its lead candidate, HY-001, is a potent and selective URAT1 inhibitor currently in Phase 2 clinical development for the treatment of hyperuricemia and gout. Hengyang Pharmaceutical utilizes a structure-based drug design platform to optimize the pharmacological properties of its pipeline candidates. The company is strategically located in the Nanjing Jiangbei New Area, leveraging the region's robust life sciences ecosystem. Through its commitment to scientific excellence, Hengyang aims to deliver safer and more effective treatment options to patients globally.